Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | SVP & Chief Operating Officer | February 25, 2020 | February 26, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date February 25, 2020 · Filed February 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2030-02-24 | Direct | 8,000 |
Reported balance
After 2020-02-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-25 · Grant · Acquired 8,000 · Balance 8,000 F3: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2025-12-22 | Direct | 28,169 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 28,169 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2025-12-22 | Direct | 8,635 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 8,635 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2025-12-23 | Direct | 4,617 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4,617 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2029-03-14 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 8,000 F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. |
| Common StockSEC Table I · non-derivative | Direct | 7,850 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,850 |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
F3: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 26, 2020 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000891839-20-000051 · edgar.xml · derivative · entry 6 Watkins Raymond E. · CIK 0001747774 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-02-24 F3 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-19-000050 · edgar.xml · derivative · entry 5 Watkins Raymond E. · CIK 0001747774 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-03-14 F3 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.